Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase 2b clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase 1 clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease. In addition, the company holds global rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase 3 clinical trial. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone919-275-1933
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.88 million
Profitability
Miscellaneous
Employees5
OptionableOptionable
Innovate Biopharmaceuticals (NASDAQ:INNT) Frequently Asked Questions
What is Innovate Biopharmaceuticals' stock symbol?
Innovate Biopharmaceuticals trades on the NASDAQ under the ticker symbol "INNT."
How were Innovate Biopharmaceuticals' earnings last quarter?
Innovate Biopharmaceuticals Inc (NASDAQ:INNT) announced its earnings results on Tuesday, November, 13th. The company reported ($0.03) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.18. View Innovate Biopharmaceuticals' Earnings History.
When is Innovate Biopharmaceuticals' next earnings date?
What price target have analysts set for INNT?
2 brokerages have issued 12-month price objectives for Innovate Biopharmaceuticals' shares. Their forecasts range from $35.00 to $35.00. On average, they anticipate Innovate Biopharmaceuticals' share price to reach $35.00 in the next twelve months. This suggests a possible upside of 1,469.5% from the stock's current price. View Analyst Price Targets for Innovate Biopharmaceuticals.
What is the consensus analysts' recommendation for Innovate Biopharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innovate Biopharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Innovate Biopharmaceuticals.
What are Wall Street analysts saying about Innovate Biopharmaceuticals stock?
Here are some recent quotes from research analysts about Innovate Biopharmaceuticals stock:
- 1. According to Zacks Investment Research, "Innovate Biopharmaceuticals, Inc. is a clinical stage biotechnology company. It focused on developing novel medicines for autoimmune/ inflammatory disease. The company's pipeline includes drug candidates for celiac disease, an unmet need, and ulcerative colitis. Its products includes INN-202 for the treatment of Celiac Disease with fast track designation, INN-108 for Inflammatory Bowel Disorders, mild to moderate Ulcerative Colitis and a GI orphan disease in a convenient liquid formulation, INN-329 for Magnetic Resonance Cholangiopancreatography which are in clinical stages. Innovate Biopharmaceuticals Inc., formerly known as Monster Digital, Inc., is based in SIMI VALLEY, United States. " (10/17/2018)
- 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We utilize a composite discounted cash flow (DCF)-based analysis methodology, which ascribes $750M to INN-202 in celiac disease (70% probability of success based on positive Phase 2b data and 15% discount rate), $400M to INN-108 in ulcerative colitis (65% probability of success and 12% discount rate), and $130M to another formulation of larazotide, designated INN-217, for treatment of NASH (35% probability of success, along with a 15% discount rate)." (8/1/2018)
Has Innovate Biopharmaceuticals been receiving favorable news coverage?
News articles about INNT stock have been trending positive on Monday, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Innovate Biopharmaceuticals earned a news sentiment score of 2.3 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the next few days.
Who are some of Innovate Biopharmaceuticals' key competitors?
Some companies that are related to Innovate Biopharmaceuticals include Paratek Pharmaceuticals (PRTK), MannKind (MNKD), Syros Pharmaceuticals (SYRS), Acer Therapeutics (ACER), Avid Bioservices (CDMO), LifeVantage (LFVN), resTORbio (TORC), Dova Pharmaceuticals (DOVA), Strongbridge Biopharma (SBBP), Xeris Pharmaceuticals (XERS), Tocagen (TOCA), Athersys (ATHX), MEI Pharma (MEIP), Aratana Therapeutics (PETX) and Arbutus Biopharma (ABUS).
Who are Innovate Biopharmaceuticals' key executives?
Innovate Biopharmaceuticals' management team includes the folowing people:
- Mr. Sandeep Laumas M.D., Exec. Chairman (Age 50)
- Dr. Christopher P. Prior, CEO & Director (Age 67)
- Mr. Jay P. Madan M.S., Pres, Chief Bus. Officer, Interim Principal Financial & Accounting Officer and Director (Age 54)
- Jerry Gardner M.D., Head of Clinical Strategy
- Ms. Kendyle Woodard, Director
Who are Innovate Biopharmaceuticals' major shareholders?
Innovate Biopharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.83%), Geode Capital Management LLC (0.65%), Bank of New York Mellon Corp (0.26%), Magnus Financial Group LLC (0.19%), GSA Capital Partners LLP (0.10%) and Rhumbline Advisers (0.09%). Company insiders that own Innovate Biopharmaceuticals stock include Christopher P Prior, June Sherie Almenoff, Roy Proujansky and Sandeep Laumas. View Institutional Ownership Trends for Innovate Biopharmaceuticals.
Which major investors are buying Innovate Biopharmaceuticals stock?
INNT stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Magnus Financial Group LLC, Geode Capital Management LLC, Bank of New York Mellon Corp, GSA Capital Partners LLP and Rhumbline Advisers. Company insiders that have bought Innovate Biopharmaceuticals stock in the last two years include Christopher P Prior, June Sherie Almenoff, Roy Proujansky and Sandeep Laumas. View Insider Buying and Selling for Innovate Biopharmaceuticals.
How do I buy shares of Innovate Biopharmaceuticals?
Shares of INNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Innovate Biopharmaceuticals' stock price today?
One share of INNT stock can currently be purchased for approximately $2.23.
How big of a company is Innovate Biopharmaceuticals?
Innovate Biopharmaceuticals has a market capitalization of $58.14 million and generates $1.88 million in revenue each year. Innovate Biopharmaceuticals employs 5 workers across the globe.
What is Innovate Biopharmaceuticals' official website?
How can I contact Innovate Biopharmaceuticals?
Innovate Biopharmaceuticals' mailing address is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. The company can be reached via phone at 919-275-1933 or via email at [email protected]
MarketBeat Community Rating for Innovate Biopharmaceuticals (NASDAQ INNT)
MarketBeat's community ratings are surveys of what our community members think about Innovate Biopharmaceuticals and other stocks. Vote "Outperform" if you believe INNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
